Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice

Study Identifier
P10-681
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Kidney Disease
  • Secondary Hyperparathyroidism
  • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    The purpose of this study is to obtain data on the safety and effectiveness of Zemplar® (paricalcitol) injection and paricalcitol capsules in real-life clinical practice. Participants, who have been treated with paricalcitol in-label in an everyday setting, have been included into this study. A period of 12 months has been chosen in order to also obtain experience on the maintenance dose and treatment optimization with paricalcitol injection and paricalcitol capsules in long-term use.

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 64522
    Feldkirch, Austria, 6800
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 53506
    Graz, Austria, 8010
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 53524
    Graz, Austria, 8036
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 74733
    Innsbruck, Austria, 6020
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 64523
    Rottenmann, Austria, 8786
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 53525
    Salzburg, Austria, 5020
    Status
    Not applicable
    Showing {first} - {last} of {total} Results